Amylyx Pharmaceuticals (AMLX) EV to EBITDA (2022 - 2026)

Amylyx Pharmaceuticals has reported EV to EBITDA for 5 years, with the latest figure at 38.29 in Q2 2026.

• On a quarterly basis, EV to EBITDA fell 320.01% year-over-year to 38.29 in Q2 2026; TTM through Jun 2026 was 10.79, a 444.13% decrease from a year earlier, with the FY2025 full-year figure at 6.59, down 2401.91% from the prior year.
• EV to EBITDA was 38.29 for Q2 2026 at Amylyx Pharmaceuticals, down from 28.86 in the prior quarter.
• The five-year high for EV to EBITDA was 323.32 in Q4 2023, with the low at 790.51 in Q1 2023.
• Average EV to EBITDA over 5 years is 33.57, with a median of 9.66 recorded in 2022.
• The sharpest annual moves came in 2023 and 2025: EV to EBITDA soared 783.08% in 2023, then sank 19684.56% in 2025.
• Over 5 years, EV to EBITDA stood at 47.33 in 2022, then jumped by 783.08% to 323.32 in 2023, then tumbled by 100.63% to 2.04 in 2024, then plunged by 1253.35% to 27.6 in 2025, then sank by 38.7% to 38.29 in 2026.
• The last three EV to EBITDA figures came in at 38.29 (Q2 2026), 28.86 (Q1 2026), and 27.6 (Q4 2025), per Business Quant data.